Medtronic is trying to prove that a long stretch of mid-single-digit growth was a portfolio problem rather than a franchise problem, and the latest quarter is the cleanest evidence yet that cardiac ablation and the core implant businesses can carry a faster run-rate. Worldwide sales reached $9.8 billion. That print rose 13.7 percent both as reported and on an organic basis, and management lifted full-year organic growth guidance by fifty basis points. The catch is the calendar. The current fiscal year is a fifty-three week year, and the extra selling week added about $570 million to the top line. Strip that week and underlying organic growth sits near seven percent, which is still the strongest clean quarter in nearly eight years outside the pandemic distortion. The investment debate is whether that underlying rate is a new floor or a one-quarter burst powered by pulsed-field ablation share gains.
The extra week is not the whole story. Cardiac Ablation Solutions grew 88 percent worldwide, including 139 percent in the United States. Affera and the Sphere Nine catheter took another nine points of domestic share as they became the workhorse in high-volume electrophysiology labs. Cardiovascular as a whole rose 18.9 percent organically, led by mid-teens growth in Cardiac Rhythm Management on Micra, OmniaSecure, and Aurora. Cranial and Spinal Technologies and Surgical each delivered high-single to low-double-digit organic growth, which is the evidence that the acceleration is broader than one catheter franchise. The counterargument is that the earnings raise was thinner than the sales raise. Adjusted diluted earnings moved only the floor of the range, to $5.94, while the ceiling stayed at $6.00, and management is reinvesting part of the upside rather than dropping it to the bottom line.
Two weeks after the print, Medtronic launched an exchange offer to split off its remaining stake in MiniMed, the diabetes business that completed an initial public offering in March and still sits inside the consolidated results. Shareholders can swap ordinary shares for MiniMed stock at a seven percent discount, in a transaction structured to be generally tax-free, with an expiration targeted for early October if the offer is not extended. Completing that split-off would retire Medtronic shares, lift reported margins, and leave a company concentrated on cardiovascular, neuroscience, and surgical. Diabetes still contributed $843 million in the quarter, so the exit is not a rounding error. The question the next several quarters have to answer is whether ablation share, the MiniMed exit, and the core implant engine can keep organic growth near the newly raised band once the extra week rolls off.